In HCC, the rise of transcription factor E26 transformation-specific-1 (Ets-1) leads to the expression of GPX2, causing mitochondrial damage and a significant reduction in mitochondrial ROS production, resulting in sorafenib resistance [104]. The gene discussed is GPX2; the disease is hepatocellular carcinoma.